The role of notch signaling in bone development and disease

Hormones

Volumn 13, Issue 1, 2014, Pages 24-37

  Yavropoulou, Maria P ^a   Yovos, John G ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Bone; Cartilage; Notch signaling; Osteoblasts; Osteoclasts

Indexed keywords

JAGGED1; NOTCH RECEPTOR; NOTCH2 RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR;

ALAGILLE SYNDROME; BINDING AFFINITY; BONE CANCER; BONE CELL; BONE DISEASE; BONE METASTASIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROGENESIS; FUCOSYLATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; JARCHO LEVIN SYNDROME; LIGAND BINDING; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN CLEAVAGE; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN POLYMORPHISM; PROTEIN SYNTHESIS; REVIEW; SPONDYLOCOSTAL DYSOSTOSIS TYPE 1; SPONDYLOCOSTAL DYSOSTOSIS TYPE 2; SPONDYLOCOSTAL DYSOSTOSIS TYPE 3; BONE DEVELOPMENT; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

BONE DEVELOPMENT; BONE DISEASES; HUMANS; OSTEOGENESIS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84899634214     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401318     Document Type: Review

References (80)

1. Artavanis-Tsakonas S, Rand MD, Lake RJ, 1999 Notch signaling: cell fate control and signal integration in development. Science 284: 770-776.
2. Lewis J, 1998 Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol 9: 583-589.
3. Bray S, 1998 Notch signalling in Drosophila: three ways to use a pathway. Semin Cell Dev Biol 9: 591-597.
4. Joutel A, Tournier-Lasserve E, 1998 Notch signalling pathway and human diseases. Semin Cell Dev Biol 9: 619-625.
5. Schweisguth F, 2004 Regulation of notch signaling activity. Curr Biol 14: R129-138.
6. Ehebauer M, Hayward P, Arias AM, 2006 Notch, a universal arbiter of cell fate decisions. Science 314: 1414-1415.
7. Ehebauer M, Hayward P, Martinez-Arias A, 2006 Notch signaling pathway. Sci STKE 2006: cm7.
8. Kopan R, Ilagan MX, 2009 The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137: 216-233.
9. Vodovar N, Schweisguth F, 2008 Functions of Ofucosyltransferase in Notch trafficking and signaling: towards the end of a controversy? J Biol 7: 7.
10. Zhang XP, Zheng G, Zou L, et al, 2008 Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem 307: 101-108.
11. D'Souza B, Miyamoto A, Weinmaster G, 2008 The many facets of Notch ligands. Oncogene 27: 5148-5167.
12. Ilagan MX, Kopan R, 2007 SnapShot: notch signaling pathway. Cell 128: 1246.
13. Haines N, Irvine KD, 2003 Glycosylation regulates Notch signalling. Nat Rev Mol Cell Biol 4: 786-797.
14. Rampal R, Luther KB, Haltiwanger RS, 2007 Notch signaling in normal and disease States: possible therapies related to glycosylation. Curr Mol Med 7: 427-445.
15. Stanley P, 2007 Regulation of Notch signaling by glycosylation. Curr Opin Struct Biol 17: 530-535.
16. Sato T, Diehl TS, Narayanan S, et al, 2007 Active gamma-secretase complexes contain only one of each component. J Biol Chem 282: 33985-33993.
17. Nakashima K, de Crombrugghe B, 2003 Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet 19: 458-466.
18. Karsenty G, Wagner EF, 2002 Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2: 389-406.
19. Dong Y, Jesse AM, Kohn A, et al, 2010 RBPjkappadependent Notch signaling regulates mesenchymal progenitor cell proliferation and differentiation during skeletal development. Development 137: 1461-1471.
20. Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ, 2002 Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis 33: 77-80.
21. Hilton MJ, Tu X, Wu X, et al, 2008 Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 14: 306-314.
22. Lefebvre V, Huang W, Harley VR, Goodfellow PN, de Crombrugghe B, 1997 SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol 17: 2336-2346.
23. Karlsson C, Lindahl A, 2009 Notch signaling in chondrogenesis. Int Rev Cell Mol Biol 275: 65-88.
24. Grogan SP, Olee T, Hiraoka K, Lotz MK, 2008 Repression of chondrogenesis through binding of notch signaling proteins HES-1 and HEY-1 to N-box domains in the COL2A1 enhancer site. Arthritis Rheum 58: 2754-2763.
25. Chen S, Tao J, Bae Y, et al, 2013 Notch gain of function inhibits chondrocyte differentiation via Rbpj-dependent suppression of Sox9. J Bone Miner Res 28: 649-659.
26. Mead TJ, Yutzey KE, 2009 Notch pathway regulation of chondrocyte differentiation and proliferation during appendicular and axial skeleton development. Proc Natl Acad Sci U S A 106: 14420-14425.
27. Kohn A, Dong Y, Mirando AJ, et al, 2012 Cartilagespecific RBPjkappa-dependent and-independent Notch signals regulate cartilage and bone development. Development 139: 1198-1212.
28. Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E, 2008 Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 149: 3890-3899.
29. Engin F, Yao Z, Yang T, et al, 2008 Dimorphic effects of Notch signaling in bone homeostasis. Nat Med 14: 299-305.
30. Canalis E, Parker K, Feng JQ, Zanotti S, 2013 Osteoblast lineage-specific effects of notch activation in the skeleton. Endocrinology 154: 623-634.
31. Kalajzic I, Kalajzic Z, Kaliterna M, et al, 2002 Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. J Bone Miner Res 17: 15-25.
32. Kalajzic I, Staal A, Yang WP, et al, 2005 Expression profile of osteoblast lineage at defined stages of differentiation. J Biol Chem 280: 24618-24626.
33. Zamurovic N, Cappellen D, Rohner D, Susa M, 2004 Coordinated activation of notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2 transcriptional activity. J Biol Chem 279: 37704-37715.
34. Sciaudone M, Gazzerro E, Priest L, Delany AM, Canalis E, 2003 Notch 1 impairs osteoblastic cell differentiation. Endocrinology 144: 5631-5639.
35. Tezuka K, Yasuda M, Watanabe N, et al, 2002 Stimulation of osteoblastic cell differentiation by Notch. J Bone Miner Res 17: 231-239.
36. Nobta M, Tsukazaki T, Shibata Y, et al, 2005 Critical regulation of bone morphogenetic protein-induced osteoblastic differentiation by Delta1/Jagged1-activated Notch1 signaling. J Biol Chem 280: 15842-15848.
37. Deregowski V, Gazzerro E, Priest L, Rydziel S, Canalis E, 2006 Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling. J Biol Chem 281: 6203-6210.
38. McLarren KW, Lo R, Grbavec D, Thirunavukkarasu K, Karsenty G, Stifani S, 2000 The mammalian basic helix loop helix protein HES-1 binds to and modulates the transactivating function of the runt-related factor Cbfa1. J Biol Chem 275: 530-538.
39. Shen Q, Christakos S, 2005 The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. J Biol Chem 280: 40589-40598.
40. Zhang Y, Lian JB, Stein JL, van Wijnen AJ, Stein GS, 2009 The Notch-responsive transcription factor Hes-1 attenuates osteocalcin promoter activity in osteoblastic cells. J Cell Biochem 108: 651-659.
41. Teitelbaum SL, 2007 Osteoclasts: what do they do and how do they do it? Am J Pathol 170: 427-435.
42. Bai S, Kopan R, Zou W, et al, 2008 NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem 283: 6509-6518.
43. Yamada T, Yamazaki H, Yamane T, et al, 2003 Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. Blood 101: 2227-2234.
44. Fukushima H, Nakao A, Okamoto F, et al, 2008 The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis. Mol Cell Biol 28: 6402-6412.
45. Zanotti S, Smerdel-Ramoya A, Canalis E, 2011 HES1 (hairy and enhancer of split 1) is a determinant of bone mass. J Biol Chem 286: 2648-2657.
46. Gucev ZS, Tasic V, Pop-Jordanova N, et al, 2010 Autosomal dominant spondylocostal dysostosis in three generations of a Macedonian family: Negative mutation analysis of DLL3, MESP2, HES7, and LFNG. Am J Med Genet A 152A: 1378-1382.
47. Lavy NW, Palmer CG, Merritt AD, 1966 A syndrome of bizarre vertebral anomalies. J Pediatr 69: 1121-1125.
48. Bulman MP, Kusumi K, Frayling TM, et al, 2000 Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis. Nat Genet 24: 438-441.
49. Saga Y, Hata N, Koseki H, Taketo MM, 1997 Mesp2: a novel mouse gene expressed in the presegmented mesoderm and essential for segmentation initiation. Genes Dev 11: 1827-1839.
50. Makino Y, Takahashi Y, Tanabe R, et al, 2013 Spatiotemporal disorder in the axial skeleton development of the Mesp2-null mouse: a model of spondylocostal dysostosis and spondylothoracic dysostosis. Bone 53: 248-258.
51. Sparrow DB, Chapman G, Wouters MA, et al, 2006 Mutation of the LUNATIC FRINGE gene in humans causes spondylocostal dysostosis with a severe vertebral phenotype. Am J Hum Genet 78: 28-37.
52. Dunwoodie SL, 2009 Reprint of mutation of the fucosespecific beta1,3 N-acetylglucosaminyltransferase LFNG results in abnormal formation of the spine. Biochim Biophys Acta 1792: 862-873.
53. Dunwoodie SL, 2009 Mutation of the fucose-specific beta1,3 N-acetylglucosaminyltransferase LFNG results in abnormal formation of the spine. Biochim Biophys Acta 1792: 100-111.
54. Zhang N, Norton CR, Gridley T, 2002 Segmentation defects of Notch pathway mutants and absence of a synergistic phenotype in lunatic fringe/radical fringe double mutant mice. Genesis 33: 21-28.
55. Kusumi K, Mimoto MS, Covello KL, Beddington RS, Krumlauf R, Dunwoodie SL, 2004 Dll3 pudgy mutation differentially disrupts dynamic expression of somite genes. Genesis 39: 115-121.
56. Sparrow DB, Guillen-Navarro E, Fatkin D, Dunwoodie SL, 2008 Mutation of Hairy-and-Enhancer-of-Split-7 in humans causes spondylocostal dysostosis. Hum Mol Genet 17: 3761-3766.
57. Sparrow DB, Sillence D, Wouters MA, Turnpenny PD, Dunwoodie SL, 2010 Two novel missense mutations in HAIR Y-AND-ENHANCER-OF-SPLIT-7 in a family with spondylocostal dysostosis. Eur J Hum Genet 18: 674-679.
58. Alagille D, Estrada A, Hadchouel M, Gautier M, Odievre M, Dommergues JP, 1987 Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr 110: 195-200.
59. Morrissette JD, Colliton RP, Spinner NB, 2001 Defective intracellular transport and processing of JAG1 missense mutations in Alagille syndrome. Hum Mol Genet 10: 405-413.
60. Kamath BM, Bauer RC, Loomes KM, et al, 2012 NOTCH2 mutations in Alagille syndrome. J Med Genet 49: 138-144.
61. McCright B, Lozier J, Gridley T, 2002 A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 129: 1075-1082.
62. Humphreys R, Zheng W, Prince LS, et al, 2012 Cranial neural crest ablation of Jagged1 recapitulates the craniofacial phenotype of Alagille syndrome patients. Hum Mol Genet 21: 1374-1383.
63. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA, 1999 Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 29: 822-829.
64. Riely CA, Cotlier E, Jensen PS, Klatskin G, 1979 Arteriohepatic dysplasia: a benign syndrome of intrahepatic cholestasis with multiple organ involvement. Ann Intern Med 91: 520-527.
65. Olsen IE, Ittenbach RF, Rovner AJ, et al, 2005 Deficits in size-adjusted bone mass in children with Alagille syndrome. J Pediatr Gastroenterol Nutr 40: 76-82.
66. Kung AW, Xiao SM, Cherny S, et al, 2010 Association of JAG1 with bone mineral density and osteoporotic fractures: a genome-wide association study and followup replication studies. Am J Hum Genet 86: 229-239.
67. Simpson MA, Irving MD, Asilmaz E, et al, 2011 Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss. Nat Genet 43: 303-305.
68. Antoniades K, Kaklamanos E, Kavadia S, Hatzistilianou M, Antoniades V, 2003 Hajdu-Cheney syndrome (acroosteolysis): a case report of dental interest. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95: 725-731.
69. Brennan AM, Pauli RM, 2001 Hajdu--Cheney syndrome: evolution of phenotype and clinical problems. Am J Med Genet 100: 292-310.
70. Udell J, Schumacher HR, Jr., Kaplan F, Fallon MD, 1986 Idiopathic familial acroosteolysis: histomorphometric study of bone and literature review of the Hajdu-Cheney syndrome. Arthritis Rheum 29: 1032-1038.
71. Brown DM, Bradford DS, Gorlin RJ, et al, 1976 The acro-osteolysis syndrome: Morphologic and biochemical studies. J Pediatr 88: 573-580.
72. Galli-Tsinopoulou A, Kyrgios I, Giza S, Giannopoulou EM, Maggana I, Laliotis N, 2012 Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney syndrome. Minerva Endocrinol 37: 283-289.
73. Weng AP, Ferrando AA, Lee W, et al, 2004 Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271.
74. Leong KG, Karsan A, 2006 Recent insights into the role of Notch signaling in tumorigenesis. Blood 107: 2223-2233.
75. Engin F, Bertin T, Ma O, et al, 2009 Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 18: 1464-1470.
76. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP, 2008 Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 14: 2962-2969.
77. Zhang Z, Wang H, Ikeda S, et al, 2010 Notch3 in human breast cancer cell lines regulates osteoblast-cancer cell interactions and osteolytic bone metastasis. Am J Pathol 177: 1459-1469.
78. Sethi N, Dai X, Winter CG, Kang Y, 2011 Tumorderived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19: 192-205.
79. Noguera-Troise I, Daly C, Papadopoulos NJ, et al, 2006 Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444: 1032-1037.
80. Nickoloff BJ, Osborne BA, Miele L, 2003 Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22: 6598-6608.